nodes	percent_of_prediction	percent_of_DWPC	metapath
Orlistat—obesity—type 2 diabetes mellitus	0.563	1	CtDrD
Orlistat—CYP3A4—type 2 diabetes mellitus	0.0965	1	CbGaD
Orlistat—CYP3A4—Linagliptin—type 2 diabetes mellitus	0.0143	0.164	CbGbCtD
Orlistat—CYP3A4—Sitagliptin—type 2 diabetes mellitus	0.0127	0.146	CbGbCtD
Orlistat—CYP3A4—Glipizide—type 2 diabetes mellitus	0.0117	0.134	CbGbCtD
Orlistat—CYP3A4—Repaglinide—type 2 diabetes mellitus	0.0102	0.117	CbGbCtD
Orlistat—CYP3A4—Pioglitazone—type 2 diabetes mellitus	0.00922	0.106	CbGbCtD
Orlistat—CYP3A4—Nateglinide—type 2 diabetes mellitus	0.00698	0.0801	CbGbCtD
Orlistat—CYP3A4—Irbesartan—type 2 diabetes mellitus	0.0067	0.0768	CbGbCtD
Orlistat—CYP3A4—Bromocriptine—type 2 diabetes mellitus	0.00633	0.0726	CbGbCtD
Orlistat—CYP3A4—Glyburide—type 2 diabetes mellitus	0.00472	0.0541	CbGbCtD
Orlistat—CYP3A4—Losartan—type 2 diabetes mellitus	0.00432	0.0495	CbGbCtD
Orlistat—ABHD16A—islet of Langerhans—type 2 diabetes mellitus	0.00213	0.0673	CbGeAlD
Orlistat—PNLIP—islet of Langerhans—type 2 diabetes mellitus	0.00199	0.0631	CbGeAlD
Orlistat—DAGLB—kidney—type 2 diabetes mellitus	0.00199	0.0629	CbGeAlD
Orlistat—DAGLB—adipose tissue—type 2 diabetes mellitus	0.00179	0.0567	CbGeAlD
Orlistat—ABHD12—retina—type 2 diabetes mellitus	0.0017	0.054	CbGeAlD
Orlistat—PLA2G7—cardiovascular system—type 2 diabetes mellitus	0.00164	0.0519	CbGeAlD
Orlistat—ABHD16A—pancreas—type 2 diabetes mellitus	0.00149	0.0473	CbGeAlD
Orlistat—ABHD16A—cortex of kidney—type 2 diabetes mellitus	0.00147	0.0464	CbGeAlD
Orlistat—PLA2G7—adipose tissue—type 2 diabetes mellitus	0.00145	0.0458	CbGeAlD
Orlistat—PNLIP—cardiovascular system—type 2 diabetes mellitus	0.00144	0.0456	CbGeAlD
Orlistat—PNLIP—pancreas—type 2 diabetes mellitus	0.0014	0.0444	CbGeAlD
Orlistat—ABHD12—cortex of kidney—type 2 diabetes mellitus	0.00137	0.0435	CbGeAlD
Orlistat—ABHD16A—adipose tissue—type 2 diabetes mellitus	0.00136	0.0429	CbGeAlD
Orlistat—ABHD12—adipose tissue—type 2 diabetes mellitus	0.00127	0.0402	CbGeAlD
Orlistat—PNLIP—adipose tissue—type 2 diabetes mellitus	0.00127	0.0402	CbGeAlD
Orlistat—DAGLB—liver—type 2 diabetes mellitus	0.00126	0.0397	CbGeAlD
Orlistat—FASN—adipose tissue—type 2 diabetes mellitus	0.00107	0.0338	CbGeAlD
Orlistat—PLA2G7—liver—type 2 diabetes mellitus	0.00101	0.0321	CbGeAlD
Orlistat—ABHD12—liver—type 2 diabetes mellitus	0.000891	0.0282	CbGeAlD
Orlistat—PNLIP—liver—type 2 diabetes mellitus	0.000891	0.0282	CbGeAlD
Orlistat—FASN—liver—type 2 diabetes mellitus	0.000748	0.0237	CbGeAlD
Orlistat—PLA2G4A—cardiovascular system—type 2 diabetes mellitus	0.000581	0.0184	CbGeAlD
Orlistat—PLA2G4A—cortex of kidney—type 2 diabetes mellitus	0.000554	0.0175	CbGeAlD
Orlistat—PLA2G4A—adipose tissue—type 2 diabetes mellitus	0.000513	0.0162	CbGeAlD
Orlistat—PLA2G4A—Glyburide—Glimepiride—type 2 diabetes mellitus	0.000399	0.17	CbGdCrCtD
Orlistat—PLA2G4A—Glyburide—Tolazamide—type 2 diabetes mellitus	0.000399	0.17	CbGdCrCtD
Orlistat—PLA2G4A—Glyburide—Gliclazide—type 2 diabetes mellitus	0.000378	0.161	CbGdCrCtD
Orlistat—PLA2G4A—Glyburide—Glipizide—type 2 diabetes mellitus	0.000378	0.161	CbGdCrCtD
Orlistat—Ethanolamine Oleate—CYP2E1—type 2 diabetes mellitus	0.000351	1	CrCbGaD
Orlistat—PLA2G4A—Glyburide—Chlorpropamide—type 2 diabetes mellitus	0.000346	0.148	CbGdCrCtD
Orlistat—PLA2G4A—Enalapril—Nateglinide—type 2 diabetes mellitus	0.000276	0.118	CbGdCrCtD
Orlistat—CYP3A4—kidney—type 2 diabetes mellitus	0.000188	0.00594	CbGeAlD
Orlistat—PLA2G4A—Enalapril—Ramipril—type 2 diabetes mellitus	0.000168	0.0716	CbGdCrCtD
Orlistat—CYP3A4—liver—type 2 diabetes mellitus	0.000119	0.00376	CbGeAlD
Orlistat—Diarrhoea—Glimepiride—type 2 diabetes mellitus	7e-05	0.000587	CcSEcCtD
Orlistat—Diarrhoea—Sitagliptin—type 2 diabetes mellitus	6.98e-05	0.000585	CcSEcCtD
Orlistat—Vomiting—Glipizide—type 2 diabetes mellitus	6.97e-05	0.000584	CcSEcCtD
Orlistat—Anaphylactic shock—Valsartan—type 2 diabetes mellitus	6.96e-05	0.000583	CcSEcCtD
Orlistat—Oedema—Valsartan—type 2 diabetes mellitus	6.96e-05	0.000583	CcSEcCtD
Orlistat—Feeling abnormal—Glyburide—type 2 diabetes mellitus	6.95e-05	0.000583	CcSEcCtD
Orlistat—Dizziness—Pioglitazone—type 2 diabetes mellitus	6.95e-05	0.000582	CcSEcCtD
Orlistat—Infection—Valsartan—type 2 diabetes mellitus	6.92e-05	0.00058	CcSEcCtD
Orlistat—Rash—Glipizide—type 2 diabetes mellitus	6.91e-05	0.000579	CcSEcCtD
Orlistat—Vision blurred—Irbesartan—type 2 diabetes mellitus	6.91e-05	0.000579	CcSEcCtD
Orlistat—Dermatitis—Glipizide—type 2 diabetes mellitus	6.91e-05	0.000579	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Gliclazide—type 2 diabetes mellitus	6.9e-05	0.000579	CcSEcCtD
Orlistat—Gastrointestinal pain—Glyburide—type 2 diabetes mellitus	6.9e-05	0.000578	CcSEcCtD
Orlistat—Headache—Glipizide—type 2 diabetes mellitus	6.87e-05	0.000576	CcSEcCtD
Orlistat—Palpitations—Metformin—type 2 diabetes mellitus	6.86e-05	0.000575	CcSEcCtD
Orlistat—Insomnia—Gliclazide—type 2 diabetes mellitus	6.85e-05	0.000574	CcSEcCtD
Orlistat—Nervous system disorder—Valsartan—type 2 diabetes mellitus	6.83e-05	0.000572	CcSEcCtD
Orlistat—Paraesthesia—Gliclazide—type 2 diabetes mellitus	6.8e-05	0.00057	CcSEcCtD
Orlistat—Ill-defined disorder—Irbesartan—type 2 diabetes mellitus	6.8e-05	0.00057	CcSEcCtD
Orlistat—Flatulence—Losartan—type 2 diabetes mellitus	6.8e-05	0.00057	CcSEcCtD
Orlistat—Hepatitis—Ramipril—type 2 diabetes mellitus	6.8e-05	0.000569	CcSEcCtD
Orlistat—Dizziness—Glimepiride—type 2 diabetes mellitus	6.77e-05	0.000567	CcSEcCtD
Orlistat—Skin disorder—Valsartan—type 2 diabetes mellitus	6.76e-05	0.000567	CcSEcCtD
Orlistat—Dysgeusia—Losartan—type 2 diabetes mellitus	6.76e-05	0.000566	CcSEcCtD
Orlistat—Dizziness—Sitagliptin—type 2 diabetes mellitus	6.75e-05	0.000565	CcSEcCtD
Orlistat—Urticaria—Glyburide—type 2 diabetes mellitus	6.7e-05	0.000562	CcSEcCtD
Orlistat—Angioedema—Irbesartan—type 2 diabetes mellitus	6.7e-05	0.000561	CcSEcCtD
Orlistat—Oedema peripheral—Ramipril—type 2 diabetes mellitus	6.69e-05	0.000561	CcSEcCtD
Orlistat—Back pain—Losartan—type 2 diabetes mellitus	6.67e-05	0.000559	CcSEcCtD
Orlistat—Abdominal pain—Glyburide—type 2 diabetes mellitus	6.67e-05	0.000559	CcSEcCtD
Orlistat—Dyspepsia—Gliclazide—type 2 diabetes mellitus	6.67e-05	0.000559	CcSEcCtD
Orlistat—Muscle spasms—Losartan—type 2 diabetes mellitus	6.63e-05	0.000556	CcSEcCtD
Orlistat—Asthenia—Bromocriptine—type 2 diabetes mellitus	6.62e-05	0.000555	CcSEcCtD
Orlistat—Chest pain—Metformin—type 2 diabetes mellitus	6.61e-05	0.000554	CcSEcCtD
Orlistat—Myalgia—Metformin—type 2 diabetes mellitus	6.61e-05	0.000554	CcSEcCtD
Orlistat—Malaise—Irbesartan—type 2 diabetes mellitus	6.61e-05	0.000554	CcSEcCtD
Orlistat—Vertigo—Irbesartan—type 2 diabetes mellitus	6.59e-05	0.000552	CcSEcCtD
Orlistat—Headache—Pioglitazone—type 2 diabetes mellitus	6.58e-05	0.000551	CcSEcCtD
Orlistat—Unspecified disorder of skin and subcutaneous tissue—Metformin—type 2 diabetes mellitus	6.57e-05	0.00055	CcSEcCtD
Orlistat—Gastrointestinal disorder—Gliclazide—type 2 diabetes mellitus	6.54e-05	0.000548	CcSEcCtD
Orlistat—Discomfort—Metformin—type 2 diabetes mellitus	6.53e-05	0.000548	CcSEcCtD
Orlistat—Fatigue—Gliclazide—type 2 diabetes mellitus	6.53e-05	0.000547	CcSEcCtD
Orlistat—Nausea—Glipizide—type 2 diabetes mellitus	6.51e-05	0.000546	CcSEcCtD
Orlistat—Vomiting—Glimepiride—type 2 diabetes mellitus	6.51e-05	0.000545	CcSEcCtD
Orlistat—Vision blurred—Losartan—type 2 diabetes mellitus	6.5e-05	0.000545	CcSEcCtD
Orlistat—Vomiting—Sitagliptin—type 2 diabetes mellitus	6.49e-05	0.000543	CcSEcCtD
Orlistat—Pain—Gliclazide—type 2 diabetes mellitus	6.48e-05	0.000543	CcSEcCtD
Orlistat—Rash—Glimepiride—type 2 diabetes mellitus	6.45e-05	0.000541	CcSEcCtD
Orlistat—Dermatitis—Glimepiride—type 2 diabetes mellitus	6.45e-05	0.00054	CcSEcCtD
Orlistat—Rash—Sitagliptin—type 2 diabetes mellitus	6.43e-05	0.000539	CcSEcCtD
Orlistat—Dermatitis—Sitagliptin—type 2 diabetes mellitus	6.43e-05	0.000538	CcSEcCtD
Orlistat—Headache—Glimepiride—type 2 diabetes mellitus	6.41e-05	0.000537	CcSEcCtD
Orlistat—Ill-defined disorder—Losartan—type 2 diabetes mellitus	6.4e-05	0.000536	CcSEcCtD
Orlistat—Cough—Irbesartan—type 2 diabetes mellitus	6.4e-05	0.000536	CcSEcCtD
Orlistat—Headache—Sitagliptin—type 2 diabetes mellitus	6.39e-05	0.000535	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Valsartan—type 2 diabetes mellitus	6.34e-05	0.000532	CcSEcCtD
Orlistat—Oedema—Metformin—type 2 diabetes mellitus	6.34e-05	0.000531	CcSEcCtD
Orlistat—Diarrhoea—Bromocriptine—type 2 diabetes mellitus	6.32e-05	0.000529	CcSEcCtD
Orlistat—Angioedema—Losartan—type 2 diabetes mellitus	6.3e-05	0.000528	CcSEcCtD
Orlistat—Infection—Metformin—type 2 diabetes mellitus	6.3e-05	0.000528	CcSEcCtD
Orlistat—Insomnia—Valsartan—type 2 diabetes mellitus	6.3e-05	0.000528	CcSEcCtD
Orlistat—Paraesthesia—Valsartan—type 2 diabetes mellitus	6.25e-05	0.000524	CcSEcCtD
Orlistat—Feeling abnormal—Gliclazide—type 2 diabetes mellitus	6.24e-05	0.000523	CcSEcCtD
Orlistat—Chest pain—Irbesartan—type 2 diabetes mellitus	6.24e-05	0.000523	CcSEcCtD
Orlistat—Myalgia—Irbesartan—type 2 diabetes mellitus	6.24e-05	0.000523	CcSEcCtD
Orlistat—Malaise—Losartan—type 2 diabetes mellitus	6.22e-05	0.000521	CcSEcCtD
Orlistat—Anxiety—Irbesartan—type 2 diabetes mellitus	6.22e-05	0.000521	CcSEcCtD
Orlistat—Hypersensitivity—Glyburide—type 2 diabetes mellitus	6.22e-05	0.000521	CcSEcCtD
Orlistat—Nervous system disorder—Metformin—type 2 diabetes mellitus	6.22e-05	0.000521	CcSEcCtD
Orlistat—Vertigo—Losartan—type 2 diabetes mellitus	6.2e-05	0.000519	CcSEcCtD
Orlistat—Unspecified disorder of skin and subcutaneous tissue—Irbesartan—type 2 diabetes mellitus	6.2e-05	0.000519	CcSEcCtD
Orlistat—Gastrointestinal pain—Gliclazide—type 2 diabetes mellitus	6.2e-05	0.000519	CcSEcCtD
Orlistat—Discomfort—Irbesartan—type 2 diabetes mellitus	6.17e-05	0.000517	CcSEcCtD
Orlistat—Skin disorder—Metformin—type 2 diabetes mellitus	6.16e-05	0.000516	CcSEcCtD
Orlistat—Immune system disorder—Ramipril—type 2 diabetes mellitus	6.14e-05	0.000514	CcSEcCtD
Orlistat—Hyperhidrosis—Metformin—type 2 diabetes mellitus	6.13e-05	0.000514	CcSEcCtD
Orlistat—Dyspepsia—Valsartan—type 2 diabetes mellitus	6.13e-05	0.000514	CcSEcCtD
Orlistat—Mediastinal disorder—Ramipril—type 2 diabetes mellitus	6.12e-05	0.000513	CcSEcCtD
Orlistat—Dizziness—Bromocriptine—type 2 diabetes mellitus	6.1e-05	0.000512	CcSEcCtD
Orlistat—Dry mouth—Irbesartan—type 2 diabetes mellitus	6.1e-05	0.000511	CcSEcCtD
Orlistat—Palpitations—Losartan—type 2 diabetes mellitus	6.1e-05	0.000511	CcSEcCtD
Orlistat—Nausea—Glimepiride—type 2 diabetes mellitus	6.08e-05	0.000509	CcSEcCtD
Orlistat—Nausea—Sitagliptin—type 2 diabetes mellitus	6.06e-05	0.000508	CcSEcCtD
Orlistat—Asthenia—Glyburide—type 2 diabetes mellitus	6.05e-05	0.000507	CcSEcCtD
Orlistat—Decreased appetite—Valsartan—type 2 diabetes mellitus	6.05e-05	0.000507	CcSEcCtD
Orlistat—Cough—Losartan—type 2 diabetes mellitus	6.02e-05	0.000504	CcSEcCtD
Orlistat—Urticaria—Gliclazide—type 2 diabetes mellitus	6.02e-05	0.000504	CcSEcCtD
Orlistat—Gastrointestinal disorder—Valsartan—type 2 diabetes mellitus	6.01e-05	0.000504	CcSEcCtD
Orlistat—Alopecia—Ramipril—type 2 diabetes mellitus	6e-05	0.000503	CcSEcCtD
Orlistat—Fatigue—Valsartan—type 2 diabetes mellitus	6e-05	0.000503	CcSEcCtD
Orlistat—Body temperature increased—Gliclazide—type 2 diabetes mellitus	5.99e-05	0.000502	CcSEcCtD
Orlistat—Abdominal pain—Gliclazide—type 2 diabetes mellitus	5.99e-05	0.000502	CcSEcCtD
Orlistat—Anaphylactic shock—Irbesartan—type 2 diabetes mellitus	5.98e-05	0.000501	CcSEcCtD
Orlistat—Oedema—Irbesartan—type 2 diabetes mellitus	5.98e-05	0.000501	CcSEcCtD
Orlistat—Pruritus—Glyburide—type 2 diabetes mellitus	5.97e-05	0.0005	CcSEcCtD
Orlistat—Mental disorder—Ramipril—type 2 diabetes mellitus	5.95e-05	0.000499	CcSEcCtD
Orlistat—Infection—Irbesartan—type 2 diabetes mellitus	5.94e-05	0.000498	CcSEcCtD
Orlistat—Malnutrition—Ramipril—type 2 diabetes mellitus	5.92e-05	0.000496	CcSEcCtD
Orlistat—Chest pain—Losartan—type 2 diabetes mellitus	5.87e-05	0.000492	CcSEcCtD
Orlistat—Myalgia—Losartan—type 2 diabetes mellitus	5.87e-05	0.000492	CcSEcCtD
Orlistat—Vomiting—Bromocriptine—type 2 diabetes mellitus	5.87e-05	0.000492	CcSEcCtD
Orlistat—Nervous system disorder—Irbesartan—type 2 diabetes mellitus	5.87e-05	0.000492	CcSEcCtD
Orlistat—Anxiety—Losartan—type 2 diabetes mellitus	5.85e-05	0.00049	CcSEcCtD
Orlistat—Rash—Bromocriptine—type 2 diabetes mellitus	5.82e-05	0.000488	CcSEcCtD
Orlistat—Dermatitis—Bromocriptine—type 2 diabetes mellitus	5.81e-05	0.000487	CcSEcCtD
Orlistat—Skin disorder—Irbesartan—type 2 diabetes mellitus	5.81e-05	0.000487	CcSEcCtD
Orlistat—Discomfort—Losartan—type 2 diabetes mellitus	5.8e-05	0.000486	CcSEcCtD
Orlistat—Dysgeusia—Ramipril—type 2 diabetes mellitus	5.79e-05	0.000485	CcSEcCtD
Orlistat—Hyperhidrosis—Irbesartan—type 2 diabetes mellitus	5.78e-05	0.000485	CcSEcCtD
Orlistat—Headache—Bromocriptine—type 2 diabetes mellitus	5.78e-05	0.000485	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Metformin—type 2 diabetes mellitus	5.78e-05	0.000484	CcSEcCtD
Orlistat—Diarrhoea—Glyburide—type 2 diabetes mellitus	5.77e-05	0.000484	CcSEcCtD
Orlistat—Dry mouth—Losartan—type 2 diabetes mellitus	5.74e-05	0.000481	CcSEcCtD
Orlistat—Gastrointestinal pain—Valsartan—type 2 diabetes mellitus	5.69e-05	0.000477	CcSEcCtD
Orlistat—Paraesthesia—Metformin—type 2 diabetes mellitus	5.69e-05	0.000477	CcSEcCtD
Orlistat—Muscle spasms—Ramipril—type 2 diabetes mellitus	5.69e-05	0.000477	CcSEcCtD
Orlistat—Oedema—Losartan—type 2 diabetes mellitus	5.63e-05	0.000472	CcSEcCtD
Orlistat—Anaphylactic shock—Losartan—type 2 diabetes mellitus	5.63e-05	0.000472	CcSEcCtD
Orlistat—Infection—Losartan—type 2 diabetes mellitus	5.59e-05	0.000469	CcSEcCtD
Orlistat—Hypersensitivity—Gliclazide—type 2 diabetes mellitus	5.58e-05	0.000468	CcSEcCtD
Orlistat—Dyspepsia—Metformin—type 2 diabetes mellitus	5.58e-05	0.000468	CcSEcCtD
Orlistat—Urticaria—Valsartan—type 2 diabetes mellitus	5.53e-05	0.000463	CcSEcCtD
Orlistat—Nervous system disorder—Losartan—type 2 diabetes mellitus	5.52e-05	0.000463	CcSEcCtD
Orlistat—Decreased appetite—Metformin—type 2 diabetes mellitus	5.51e-05	0.000462	CcSEcCtD
Orlistat—Abdominal pain—Valsartan—type 2 diabetes mellitus	5.5e-05	0.000461	CcSEcCtD
Orlistat—Ill-defined disorder—Ramipril—type 2 diabetes mellitus	5.49e-05	0.00046	CcSEcCtD
Orlistat—Nausea—Bromocriptine—type 2 diabetes mellitus	5.48e-05	0.000459	CcSEcCtD
Orlistat—Gastrointestinal disorder—Metformin—type 2 diabetes mellitus	5.47e-05	0.000459	CcSEcCtD
Orlistat—Fatigue—Metformin—type 2 diabetes mellitus	5.47e-05	0.000458	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Irbesartan—type 2 diabetes mellitus	5.45e-05	0.000457	CcSEcCtD
Orlistat—Hyperhidrosis—Losartan—type 2 diabetes mellitus	5.44e-05	0.000456	CcSEcCtD
Orlistat—Asthenia—Gliclazide—type 2 diabetes mellitus	5.44e-05	0.000456	CcSEcCtD
Orlistat—Angioedema—Ramipril—type 2 diabetes mellitus	5.41e-05	0.000453	CcSEcCtD
Orlistat—Paraesthesia—Irbesartan—type 2 diabetes mellitus	5.37e-05	0.00045	CcSEcCtD
Orlistat—Vomiting—Glyburide—type 2 diabetes mellitus	5.37e-05	0.00045	CcSEcCtD
Orlistat—Pruritus—Gliclazide—type 2 diabetes mellitus	5.36e-05	0.000449	CcSEcCtD
Orlistat—Malaise—Ramipril—type 2 diabetes mellitus	5.33e-05	0.000447	CcSEcCtD
Orlistat—Rash—Glyburide—type 2 diabetes mellitus	5.32e-05	0.000446	CcSEcCtD
Orlistat—Dermatitis—Glyburide—type 2 diabetes mellitus	5.32e-05	0.000445	CcSEcCtD
Orlistat—Vertigo—Ramipril—type 2 diabetes mellitus	5.31e-05	0.000445	CcSEcCtD
Orlistat—Headache—Glyburide—type 2 diabetes mellitus	5.29e-05	0.000443	CcSEcCtD
Orlistat—Dyspepsia—Irbesartan—type 2 diabetes mellitus	5.27e-05	0.000441	CcSEcCtD
Orlistat—Palpitations—Ramipril—type 2 diabetes mellitus	5.23e-05	0.000438	CcSEcCtD
Orlistat—Feeling abnormal—Metformin—type 2 diabetes mellitus	5.22e-05	0.000438	CcSEcCtD
Orlistat—Decreased appetite—Irbesartan—type 2 diabetes mellitus	5.2e-05	0.000436	CcSEcCtD
Orlistat—Diarrhoea—Gliclazide—type 2 diabetes mellitus	5.18e-05	0.000434	CcSEcCtD
Orlistat—Gastrointestinal pain—Metformin—type 2 diabetes mellitus	5.18e-05	0.000434	CcSEcCtD
Orlistat—Gastrointestinal disorder—Irbesartan—type 2 diabetes mellitus	5.17e-05	0.000433	CcSEcCtD
Orlistat—Cough—Ramipril—type 2 diabetes mellitus	5.16e-05	0.000433	CcSEcCtD
Orlistat—Fatigue—Irbesartan—type 2 diabetes mellitus	5.16e-05	0.000432	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Losartan—type 2 diabetes mellitus	5.13e-05	0.00043	CcSEcCtD
Orlistat—Hypersensitivity—Valsartan—type 2 diabetes mellitus	5.13e-05	0.00043	CcSEcCtD
Orlistat—Convulsion—Ramipril—type 2 diabetes mellitus	5.13e-05	0.00043	CcSEcCtD
Orlistat—Pain—Irbesartan—type 2 diabetes mellitus	5.12e-05	0.000429	CcSEcCtD
Orlistat—Insomnia—Losartan—type 2 diabetes mellitus	5.09e-05	0.000427	CcSEcCtD
Orlistat—Paraesthesia—Losartan—type 2 diabetes mellitus	5.06e-05	0.000424	CcSEcCtD
Orlistat—Urticaria—Metformin—type 2 diabetes mellitus	5.04e-05	0.000422	CcSEcCtD
Orlistat—Myalgia—Ramipril—type 2 diabetes mellitus	5.04e-05	0.000422	CcSEcCtD
Orlistat—Chest pain—Ramipril—type 2 diabetes mellitus	5.04e-05	0.000422	CcSEcCtD
Orlistat—Anxiety—Ramipril—type 2 diabetes mellitus	5.02e-05	0.000421	CcSEcCtD
Orlistat—Nausea—Glyburide—type 2 diabetes mellitus	5.01e-05	0.00042	CcSEcCtD
Orlistat—Abdominal pain—Metformin—type 2 diabetes mellitus	5.01e-05	0.00042	CcSEcCtD
Orlistat—Dizziness—Gliclazide—type 2 diabetes mellitus	5.01e-05	0.00042	CcSEcCtD
Orlistat—Unspecified disorder of skin and subcutaneous tissue—Ramipril—type 2 diabetes mellitus	5e-05	0.000419	CcSEcCtD
Orlistat—Asthenia—Valsartan—type 2 diabetes mellitus	4.99e-05	0.000419	CcSEcCtD
Orlistat—Discomfort—Ramipril—type 2 diabetes mellitus	4.98e-05	0.000417	CcSEcCtD
Orlistat—Dyspepsia—Losartan—type 2 diabetes mellitus	4.96e-05	0.000415	CcSEcCtD
Orlistat—Feeling abnormal—Irbesartan—type 2 diabetes mellitus	4.93e-05	0.000413	CcSEcCtD
Orlistat—Pruritus—Valsartan—type 2 diabetes mellitus	4.93e-05	0.000413	CcSEcCtD
Orlistat—Dry mouth—Ramipril—type 2 diabetes mellitus	4.93e-05	0.000413	CcSEcCtD
Orlistat—Decreased appetite—Losartan—type 2 diabetes mellitus	4.89e-05	0.00041	CcSEcCtD
Orlistat—Gastrointestinal pain—Irbesartan—type 2 diabetes mellitus	4.89e-05	0.00041	CcSEcCtD
Orlistat—Fatigue—Losartan—type 2 diabetes mellitus	4.85e-05	0.000407	CcSEcCtD
Orlistat—Oedema—Ramipril—type 2 diabetes mellitus	4.83e-05	0.000405	CcSEcCtD
Orlistat—Anaphylactic shock—Ramipril—type 2 diabetes mellitus	4.83e-05	0.000405	CcSEcCtD
Orlistat—Vomiting—Gliclazide—type 2 diabetes mellitus	4.82e-05	0.000404	CcSEcCtD
Orlistat—Pain—Losartan—type 2 diabetes mellitus	4.81e-05	0.000403	CcSEcCtD
Orlistat—Rash—Gliclazide—type 2 diabetes mellitus	4.78e-05	0.0004	CcSEcCtD
Orlistat—Dermatitis—Gliclazide—type 2 diabetes mellitus	4.77e-05	0.0004	CcSEcCtD
Orlistat—Diarrhoea—Valsartan—type 2 diabetes mellitus	4.76e-05	0.000399	CcSEcCtD
Orlistat—Urticaria—Irbesartan—type 2 diabetes mellitus	4.75e-05	0.000398	CcSEcCtD
Orlistat—Headache—Gliclazide—type 2 diabetes mellitus	4.75e-05	0.000398	CcSEcCtD
Orlistat—Nervous system disorder—Ramipril—type 2 diabetes mellitus	4.73e-05	0.000397	CcSEcCtD
Orlistat—Body temperature increased—Irbesartan—type 2 diabetes mellitus	4.73e-05	0.000396	CcSEcCtD
Orlistat—Abdominal pain—Irbesartan—type 2 diabetes mellitus	4.73e-05	0.000396	CcSEcCtD
Orlistat—Skin disorder—Ramipril—type 2 diabetes mellitus	4.69e-05	0.000393	CcSEcCtD
Orlistat—Hyperhidrosis—Ramipril—type 2 diabetes mellitus	4.67e-05	0.000391	CcSEcCtD
Orlistat—Feeling abnormal—Losartan—type 2 diabetes mellitus	4.64e-05	0.000389	CcSEcCtD
Orlistat—Gastrointestinal pain—Losartan—type 2 diabetes mellitus	4.6e-05	0.000386	CcSEcCtD
Orlistat—Dizziness—Valsartan—type 2 diabetes mellitus	4.6e-05	0.000386	CcSEcCtD
Orlistat—Asthenia—Metformin—type 2 diabetes mellitus	4.55e-05	0.000381	CcSEcCtD
Orlistat—Nausea—Gliclazide—type 2 diabetes mellitus	4.5e-05	0.000377	CcSEcCtD
Orlistat—Pruritus—Metformin—type 2 diabetes mellitus	4.49e-05	0.000376	CcSEcCtD
Orlistat—Urticaria—Losartan—type 2 diabetes mellitus	4.47e-05	0.000375	CcSEcCtD
Orlistat—Abdominal pain—Losartan—type 2 diabetes mellitus	4.45e-05	0.000373	CcSEcCtD
Orlistat—Body temperature increased—Losartan—type 2 diabetes mellitus	4.45e-05	0.000373	CcSEcCtD
Orlistat—Vomiting—Valsartan—type 2 diabetes mellitus	4.43e-05	0.000371	CcSEcCtD
Orlistat—Hypersensitivity—Irbesartan—type 2 diabetes mellitus	4.41e-05	0.000369	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Ramipril—type 2 diabetes mellitus	4.4e-05	0.000369	CcSEcCtD
Orlistat—Rash—Valsartan—type 2 diabetes mellitus	4.39e-05	0.000368	CcSEcCtD
Orlistat—Dermatitis—Valsartan—type 2 diabetes mellitus	4.39e-05	0.000368	CcSEcCtD
Orlistat—Insomnia—Ramipril—type 2 diabetes mellitus	4.37e-05	0.000366	CcSEcCtD
Orlistat—Headache—Valsartan—type 2 diabetes mellitus	4.36e-05	0.000365	CcSEcCtD
Orlistat—Diarrhoea—Metformin—type 2 diabetes mellitus	4.34e-05	0.000364	CcSEcCtD
Orlistat—Paraesthesia—Ramipril—type 2 diabetes mellitus	4.34e-05	0.000363	CcSEcCtD
Orlistat—Asthenia—Irbesartan—type 2 diabetes mellitus	4.29e-05	0.00036	CcSEcCtD
Orlistat—Dyspepsia—Ramipril—type 2 diabetes mellitus	4.25e-05	0.000356	CcSEcCtD
Orlistat—Pruritus—Irbesartan—type 2 diabetes mellitus	4.23e-05	0.000355	CcSEcCtD
Orlistat—Decreased appetite—Ramipril—type 2 diabetes mellitus	4.2e-05	0.000352	CcSEcCtD
Orlistat—Dizziness—Metformin—type 2 diabetes mellitus	4.19e-05	0.000351	CcSEcCtD
Orlistat—Gastrointestinal disorder—Ramipril—type 2 diabetes mellitus	4.17e-05	0.000349	CcSEcCtD
Orlistat—Fatigue—Ramipril—type 2 diabetes mellitus	4.16e-05	0.000349	CcSEcCtD
Orlistat—Hypersensitivity—Losartan—type 2 diabetes mellitus	4.15e-05	0.000348	CcSEcCtD
Orlistat—Nausea—Valsartan—type 2 diabetes mellitus	4.14e-05	0.000347	CcSEcCtD
Orlistat—Diarrhoea—Irbesartan—type 2 diabetes mellitus	4.09e-05	0.000343	CcSEcCtD
Orlistat—Asthenia—Losartan—type 2 diabetes mellitus	4.04e-05	0.000339	CcSEcCtD
Orlistat—Vomiting—Metformin—type 2 diabetes mellitus	4.03e-05	0.000338	CcSEcCtD
Orlistat—Rash—Metformin—type 2 diabetes mellitus	4e-05	0.000335	CcSEcCtD
Orlistat—Dermatitis—Metformin—type 2 diabetes mellitus	3.99e-05	0.000335	CcSEcCtD
Orlistat—Pruritus—Losartan—type 2 diabetes mellitus	3.98e-05	0.000334	CcSEcCtD
Orlistat—Feeling abnormal—Ramipril—type 2 diabetes mellitus	3.98e-05	0.000333	CcSEcCtD
Orlistat—Headache—Metformin—type 2 diabetes mellitus	3.97e-05	0.000333	CcSEcCtD
Orlistat—Dizziness—Irbesartan—type 2 diabetes mellitus	3.96e-05	0.000332	CcSEcCtD
Orlistat—Gastrointestinal pain—Ramipril—type 2 diabetes mellitus	3.95e-05	0.000331	CcSEcCtD
Orlistat—Diarrhoea—Losartan—type 2 diabetes mellitus	3.85e-05	0.000323	CcSEcCtD
Orlistat—Urticaria—Ramipril—type 2 diabetes mellitus	3.84e-05	0.000321	CcSEcCtD
Orlistat—Body temperature increased—Ramipril—type 2 diabetes mellitus	3.82e-05	0.00032	CcSEcCtD
Orlistat—Abdominal pain—Ramipril—type 2 diabetes mellitus	3.82e-05	0.00032	CcSEcCtD
Orlistat—Vomiting—Irbesartan—type 2 diabetes mellitus	3.8e-05	0.000319	CcSEcCtD
Orlistat—Rash—Irbesartan—type 2 diabetes mellitus	3.77e-05	0.000316	CcSEcCtD
Orlistat—Dermatitis—Irbesartan—type 2 diabetes mellitus	3.77e-05	0.000316	CcSEcCtD
Orlistat—Nausea—Metformin—type 2 diabetes mellitus	3.77e-05	0.000316	CcSEcCtD
Orlistat—Headache—Irbesartan—type 2 diabetes mellitus	3.75e-05	0.000314	CcSEcCtD
Orlistat—Dizziness—Losartan—type 2 diabetes mellitus	3.72e-05	0.000312	CcSEcCtD
Orlistat—Vomiting—Losartan—type 2 diabetes mellitus	3.58e-05	0.0003	CcSEcCtD
Orlistat—Hypersensitivity—Ramipril—type 2 diabetes mellitus	3.56e-05	0.000298	CcSEcCtD
Orlistat—Nausea—Irbesartan—type 2 diabetes mellitus	3.55e-05	0.000298	CcSEcCtD
Orlistat—Rash—Losartan—type 2 diabetes mellitus	3.55e-05	0.000298	CcSEcCtD
Orlistat—Dermatitis—Losartan—type 2 diabetes mellitus	3.55e-05	0.000297	CcSEcCtD
Orlistat—Headache—Losartan—type 2 diabetes mellitus	3.53e-05	0.000296	CcSEcCtD
Orlistat—Asthenia—Ramipril—type 2 diabetes mellitus	3.46e-05	0.00029	CcSEcCtD
Orlistat—Pruritus—Ramipril—type 2 diabetes mellitus	3.42e-05	0.000286	CcSEcCtD
Orlistat—Nausea—Losartan—type 2 diabetes mellitus	3.34e-05	0.00028	CcSEcCtD
Orlistat—Diarrhoea—Ramipril—type 2 diabetes mellitus	3.3e-05	0.000277	CcSEcCtD
Orlistat—Dizziness—Ramipril—type 2 diabetes mellitus	3.19e-05	0.000268	CcSEcCtD
Orlistat—Vomiting—Ramipril—type 2 diabetes mellitus	3.07e-05	0.000257	CcSEcCtD
Orlistat—Rash—Ramipril—type 2 diabetes mellitus	3.04e-05	0.000255	CcSEcCtD
Orlistat—Dermatitis—Ramipril—type 2 diabetes mellitus	3.04e-05	0.000255	CcSEcCtD
Orlistat—Headache—Ramipril—type 2 diabetes mellitus	3.02e-05	0.000253	CcSEcCtD
Orlistat—Nausea—Ramipril—type 2 diabetes mellitus	2.87e-05	0.00024	CcSEcCtD
Orlistat—PNLIP—Disease—EGFR—type 2 diabetes mellitus	6.6e-06	6.62e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—SLC9A1—type 2 diabetes mellitus	6.59e-06	6.61e-05	CbGpPWpGaD
Orlistat—FASN—Disease—PTGS2—type 2 diabetes mellitus	6.59e-06	6.61e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PRKAA1—type 2 diabetes mellitus	6.56e-06	6.58e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—CETP—type 2 diabetes mellitus	6.51e-06	6.54e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—MTNR1B—type 2 diabetes mellitus	6.5e-06	6.52e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—SPRY2—type 2 diabetes mellitus	6.5e-06	6.52e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—GNB3—type 2 diabetes mellitus	6.41e-06	6.43e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—AKT1—type 2 diabetes mellitus	6.4e-06	6.42e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—PIK3R1—type 2 diabetes mellitus	6.38e-06	6.4e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—NOS3—type 2 diabetes mellitus	6.38e-06	6.4e-05	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—SRC—type 2 diabetes mellitus	6.36e-06	6.38e-05	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—SRC—type 2 diabetes mellitus	6.36e-06	6.38e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—RBP4—type 2 diabetes mellitus	6.33e-06	6.36e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—GLP1R—type 2 diabetes mellitus	6.33e-06	6.36e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—MMP3—type 2 diabetes mellitus	6.32e-06	6.34e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—AVP—type 2 diabetes mellitus	6.32e-06	6.34e-05	CbGpPWpGaD
Orlistat—FASN—Metabolism—ALB—type 2 diabetes mellitus	6.3e-06	6.33e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CCKAR—type 2 diabetes mellitus	6.23e-06	6.25e-05	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—VEGFA—type 2 diabetes mellitus	6.2e-06	6.22e-05	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—VEGFA—type 2 diabetes mellitus	6.2e-06	6.22e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—ALB—type 2 diabetes mellitus	6.07e-06	6.1e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PSMD6—type 2 diabetes mellitus	6.06e-06	6.08e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—SNAP25—type 2 diabetes mellitus	6.06e-06	6.08e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—SREBF1—type 2 diabetes mellitus	6.06e-06	6.08e-05	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—CASP3—type 2 diabetes mellitus	6.05e-06	6.07e-05	CbGpPWpGaD
Orlistat—FASN—Metabolism—PIK3R1—type 2 diabetes mellitus	6.03e-06	6.05e-05	CbGpPWpGaD
Orlistat—FASN—Metabolism—NOS3—type 2 diabetes mellitus	6.03e-06	6.05e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—EDN1—type 2 diabetes mellitus	6.01e-06	6.03e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—CTGF—type 2 diabetes mellitus	5.95e-06	5.97e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—HMGCR—type 2 diabetes mellitus	5.89e-06	5.91e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—PIK3R1—type 2 diabetes mellitus	5.81e-06	5.83e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—ADRA2A—type 2 diabetes mellitus	5.77e-06	5.79e-05	CbGpPWpGaD
Orlistat—CYP3A4—Biological oxidations—GSTM1—type 2 diabetes mellitus	5.75e-06	5.77e-05	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—MMP9—type 2 diabetes mellitus	5.72e-06	5.74e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—ADCY5—type 2 diabetes mellitus	5.71e-06	5.73e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—AKT1—type 2 diabetes mellitus	5.69e-06	5.71e-05	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—TGFB1—type 2 diabetes mellitus	5.69e-06	5.71e-05	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—TGFB1—type 2 diabetes mellitus	5.69e-06	5.71e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metapathway biotransformation—GSTM1—type 2 diabetes mellitus	5.67e-06	5.69e-05	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—NFKB1—type 2 diabetes mellitus	5.66e-06	5.68e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—ATP2A2—type 2 diabetes mellitus	5.65e-06	5.67e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—IAPP—type 2 diabetes mellitus	5.61e-06	5.63e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—INSR—type 2 diabetes mellitus	5.58e-06	5.6e-05	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—EGFR—type 2 diabetes mellitus	5.58e-06	5.6e-05	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—EGFR—type 2 diabetes mellitus	5.58e-06	5.6e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—CYP2E1—type 2 diabetes mellitus	5.54e-06	5.56e-05	CbGpPWpGaD
Orlistat—FASN—Metabolism—PTGS2—type 2 diabetes mellitus	5.52e-06	5.53e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—TRPC6—type 2 diabetes mellitus	5.48e-06	5.5e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—SLC2A1—type 2 diabetes mellitus	5.48e-06	5.5e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—CYP1A2—type 2 diabetes mellitus	5.48e-06	5.5e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—PPP2CA—type 2 diabetes mellitus	5.47e-06	5.49e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—AGTR2—type 2 diabetes mellitus	5.45e-06	5.47e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—CCR5—type 2 diabetes mellitus	5.37e-06	5.39e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—CYP3A4—type 2 diabetes mellitus	5.34e-06	5.36e-05	CbGpPWpGaD
Orlistat—FASN—Disease—SRC—type 2 diabetes mellitus	5.33e-06	5.34e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—PTGS2—type 2 diabetes mellitus	5.31e-06	5.33e-05	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—SRC—type 2 diabetes mellitus	5.27e-06	5.29e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—C3—type 2 diabetes mellitus	5.25e-06	5.27e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—GCG—type 2 diabetes mellitus	5.25e-06	5.27e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—SLC2A4—type 2 diabetes mellitus	5.25e-06	5.27e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—EDNRB—type 2 diabetes mellitus	5.22e-06	5.23e-05	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—VEGFA—type 2 diabetes mellitus	5.13e-06	5.15e-05	CbGpPWpGaD
Orlistat—PNLIP—Disease—IL6—type 2 diabetes mellitus	5.07e-06	5.09e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—HTR2C—type 2 diabetes mellitus	5.06e-06	5.08e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PSMD6—type 2 diabetes mellitus	5.06e-06	5.08e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—AGT—type 2 diabetes mellitus	4.99e-06	5.01e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—EDNRA—type 2 diabetes mellitus	4.93e-06	4.94e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—CALM1—type 2 diabetes mellitus	4.91e-06	4.92e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CYBA—type 2 diabetes mellitus	4.9e-06	4.92e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—ADRA2A—type 2 diabetes mellitus	4.82e-06	4.84e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PLAT—type 2 diabetes mellitus	4.8e-06	4.82e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—GHRL—type 2 diabetes mellitus	4.8e-06	4.82e-05	CbGpPWpGaD
Orlistat—FASN—Disease—TGFB1—type 2 diabetes mellitus	4.76e-06	4.78e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CALCA—type 2 diabetes mellitus	4.74e-06	4.76e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—SRC—type 2 diabetes mellitus	4.72e-06	4.74e-05	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—TGFB1—type 2 diabetes mellitus	4.71e-06	4.73e-05	CbGpPWpGaD
Orlistat—PNLIP—Disease—AKT1—type 2 diabetes mellitus	4.68e-06	4.69e-05	CbGpPWpGaD
Orlistat—FASN—Disease—EGFR—type 2 diabetes mellitus	4.67e-06	4.68e-05	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—EGFR—type 2 diabetes mellitus	4.62e-06	4.64e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—PRKCB—type 2 diabetes mellitus	4.61e-06	4.63e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—VEGFA—type 2 diabetes mellitus	4.6e-06	4.61e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—GNB3—type 2 diabetes mellitus	4.53e-06	4.54e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PPARGC1A—type 2 diabetes mellitus	4.53e-06	4.54e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—HMOX1—type 2 diabetes mellitus	4.51e-06	4.52e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—TCF7L2—type 2 diabetes mellitus	4.47e-06	4.48e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—CAT—type 2 diabetes mellitus	4.45e-06	4.46e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PTPN1—type 2 diabetes mellitus	4.39e-06	4.41e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—GCG—type 2 diabetes mellitus	4.39e-06	4.41e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—BHMT—type 2 diabetes mellitus	4.38e-06	4.4e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—RASGRP1—type 2 diabetes mellitus	4.32e-06	4.33e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—APOB—type 2 diabetes mellitus	4.32e-06	4.33e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—NOTCH2—type 2 diabetes mellitus	4.31e-06	4.32e-05	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—IL6—type 2 diabetes mellitus	4.29e-06	4.3e-05	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—IL6—type 2 diabetes mellitus	4.29e-06	4.3e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—TGFB1—type 2 diabetes mellitus	4.22e-06	4.23e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—GSTM1—type 2 diabetes mellitus	4.2e-06	4.21e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—LPL—type 2 diabetes mellitus	4.12e-06	4.13e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—CCL2—type 2 diabetes mellitus	4.11e-06	4.12e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—AKT2—type 2 diabetes mellitus	4.04e-06	4.05e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—ADCY5—type 2 diabetes mellitus	4.03e-06	4.05e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—GPX1—type 2 diabetes mellitus	4.02e-06	4.03e-05	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—AKT1—type 2 diabetes mellitus	3.95e-06	3.97e-05	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—AKT1—type 2 diabetes mellitus	3.95e-06	3.97e-05	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—AKT1—type 2 diabetes mellitus	3.92e-06	3.93e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—CD36—type 2 diabetes mellitus	3.92e-06	3.93e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PPP2CA—type 2 diabetes mellitus	3.87e-06	3.88e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PTGDS—type 2 diabetes mellitus	3.83e-06	3.85e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—AANAT—type 2 diabetes mellitus	3.83e-06	3.85e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	3.82e-06	3.83e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—GNB3—type 2 diabetes mellitus	3.78e-06	3.8e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—AVP—type 2 diabetes mellitus	3.73e-06	3.75e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—MMP3—type 2 diabetes mellitus	3.73e-06	3.75e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—IGF2—type 2 diabetes mellitus	3.72e-06	3.73e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—MTHFR—type 2 diabetes mellitus	3.71e-06	3.72e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	3.7e-06	3.71e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	3.66e-06	3.68e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PPARA—type 2 diabetes mellitus	3.64e-06	3.65e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CDO1—type 2 diabetes mellitus	3.63e-06	3.65e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GPD2—type 2 diabetes mellitus	3.63e-06	3.65e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—APOB—type 2 diabetes mellitus	3.61e-06	3.62e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—IGF1R—type 2 diabetes mellitus	3.59e-06	3.61e-05	CbGpPWpGaD
Orlistat—FASN—Disease—IL6—type 2 diabetes mellitus	3.59e-06	3.6e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—EDN1—type 2 diabetes mellitus	3.55e-06	3.56e-05	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—IL6—type 2 diabetes mellitus	3.55e-06	3.56e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—AGT—type 2 diabetes mellitus	3.53e-06	3.54e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—CALM1—type 2 diabetes mellitus	3.47e-06	3.48e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—AK1—type 2 diabetes mellitus	3.47e-06	3.48e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—APOE—type 2 diabetes mellitus	3.45e-06	3.47e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—LPL—type 2 diabetes mellitus	3.45e-06	3.46e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—APOA1—type 2 diabetes mellitus	3.41e-06	3.43e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—ADCY5—type 2 diabetes mellitus	3.37e-06	3.38e-05	CbGpPWpGaD
Orlistat—FASN—Disease—AKT1—type 2 diabetes mellitus	3.31e-06	3.32e-05	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—AKT1—type 2 diabetes mellitus	3.28e-06	3.29e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	3.23e-06	3.24e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—SLC5A4—type 2 diabetes mellitus	3.2e-06	3.21e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—MAT1A—type 2 diabetes mellitus	3.2e-06	3.21e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CCR5—type 2 diabetes mellitus	3.17e-06	3.19e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—C3—type 2 diabetes mellitus	3.1e-06	3.11e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ENPP1—type 2 diabetes mellitus	3.09e-06	3.1e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PPP1R3C—type 2 diabetes mellitus	3.09e-06	3.1e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ND1—type 2 diabetes mellitus	3.09e-06	3.1e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—G6PC—type 2 diabetes mellitus	3.09e-06	3.1e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—HBA2—type 2 diabetes mellitus	3.09e-06	3.1e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PPARG—type 2 diabetes mellitus	3.01e-06	3.02e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GCGR—type 2 diabetes mellitus	2.99e-06	3e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—HIF1A—type 2 diabetes mellitus	2.96e-06	2.97e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—IRS2—type 2 diabetes mellitus	2.95e-06	2.96e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—INS—type 2 diabetes mellitus	2.95e-06	2.96e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—AGT—type 2 diabetes mellitus	2.95e-06	2.96e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—AKT1—type 2 diabetes mellitus	2.93e-06	2.94e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CALM1—type 2 diabetes mellitus	2.9e-06	2.91e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—LEP—type 2 diabetes mellitus	2.89e-06	2.9e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—APOE—type 2 diabetes mellitus	2.89e-06	2.9e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—APOA1—type 2 diabetes mellitus	2.86e-06	2.86e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CYTB—type 2 diabetes mellitus	2.83e-06	2.83e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—OXCT1—type 2 diabetes mellitus	2.83e-06	2.83e-05	CbGpPWpGaD
Orlistat—FASN—Metabolism—AKT1—type 2 diabetes mellitus	2.77e-06	2.78e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—SRD5A1—type 2 diabetes mellitus	2.75e-06	2.76e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PRKCB—type 2 diabetes mellitus	2.72e-06	2.73e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—ALB—type 2 diabetes mellitus	2.71e-06	2.71e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ACACA—type 2 diabetes mellitus	2.63e-06	2.64e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—HSD17B3—type 2 diabetes mellitus	2.63e-06	2.64e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—STAR—type 2 diabetes mellitus	2.63e-06	2.64e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—NOS3—type 2 diabetes mellitus	2.59e-06	2.6e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PIK3R1—type 2 diabetes mellitus	2.59e-06	2.6e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—IRS1—type 2 diabetes mellitus	2.58e-06	2.59e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ABCC8—type 2 diabetes mellitus	2.52e-06	2.53e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CBS—type 2 diabetes mellitus	2.52e-06	2.53e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—INS—type 2 diabetes mellitus	2.47e-06	2.48e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CCL2—type 2 diabetes mellitus	2.43e-06	2.44e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—COX2—type 2 diabetes mellitus	2.42e-06	2.43e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—SLC5A2—type 2 diabetes mellitus	2.42e-06	2.43e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—IGF1—type 2 diabetes mellitus	2.39e-06	2.39e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—AKT2—type 2 diabetes mellitus	2.38e-06	2.39e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—NCOA6—type 2 diabetes mellitus	2.38e-06	2.39e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—EGFR—type 2 diabetes mellitus	2.37e-06	2.38e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PTGS2—type 2 diabetes mellitus	2.37e-06	2.37e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—HSD11B1—type 2 diabetes mellitus	2.34e-06	2.35e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—UCP3—type 2 diabetes mellitus	2.34e-06	2.35e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—UCP2—type 2 diabetes mellitus	2.34e-06	2.35e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	2.27e-06	2.27e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PCK1—type 2 diabetes mellitus	2.2e-06	2.21e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	2.16e-06	2.17e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—NOS3—type 2 diabetes mellitus	2.16e-06	2.17e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—HK1—type 2 diabetes mellitus	2.06e-06	2.07e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—RELA—type 2 diabetes mellitus	2.04e-06	2.04e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GCKR—type 2 diabetes mellitus	1.99e-06	2e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—LPA—type 2 diabetes mellitus	1.99e-06	2e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—KCNJ11—type 2 diabetes mellitus	1.99e-06	2e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—HSD3B2—type 2 diabetes mellitus	1.99e-06	2e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ALDOB—type 2 diabetes mellitus	1.91e-06	1.91e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.84e-06	1.84e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.83e-06	1.83e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GLP1R—type 2 diabetes mellitus	1.77e-06	1.78e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.74e-06	1.74e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.72e-06	1.72e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.68e-06	1.69e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—SLC2A2—type 2 diabetes mellitus	1.66e-06	1.66e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CPT1A—type 2 diabetes mellitus	1.62e-06	1.63e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—MTR—type 2 diabetes mellitus	1.62e-06	1.63e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—SRC—type 2 diabetes mellitus	1.6e-06	1.61e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—NAMPT—type 2 diabetes mellitus	1.59e-06	1.6e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—HBA1—type 2 diabetes mellitus	1.58e-06	1.59e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—LIPC—type 2 diabetes mellitus	1.58e-06	1.59e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GCK—type 2 diabetes mellitus	1.58e-06	1.59e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CYP11A1—type 2 diabetes mellitus	1.57e-06	1.58e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.56e-06	1.56e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—SLC9A1—type 2 diabetes mellitus	1.54e-06	1.55e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CETP—type 2 diabetes mellitus	1.53e-06	1.53e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.43e-06	1.44e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PSMD6—type 2 diabetes mellitus	1.42e-06	1.42e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—SNAP25—type 2 diabetes mellitus	1.42e-06	1.42e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—SREBF1—type 2 diabetes mellitus	1.42e-06	1.42e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.4e-06	1.41e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CTGF—type 2 diabetes mellitus	1.39e-06	1.4e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—HMGCR—type 2 diabetes mellitus	1.38e-06	1.38e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ADRA2A—type 2 diabetes mellitus	1.35e-06	1.35e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CYP2E1—type 2 diabetes mellitus	1.3e-06	1.3e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CYP1A2—type 2 diabetes mellitus	1.28e-06	1.29e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—SLC2A1—type 2 diabetes mellitus	1.28e-06	1.29e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—SLC2A4—type 2 diabetes mellitus	1.23e-06	1.23e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GCG—type 2 diabetes mellitus	1.23e-06	1.23e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—AKT1—type 2 diabetes mellitus	1.19e-06	1.19e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—IL6—type 2 diabetes mellitus	1.08e-06	1.08e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PPARGC1A—type 2 diabetes mellitus	1.06e-06	1.06e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GNB3—type 2 diabetes mellitus	1.06e-06	1.06e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—HMOX1—type 2 diabetes mellitus	1.06e-06	1.06e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CAT—type 2 diabetes mellitus	1.04e-06	1.04e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—APOB—type 2 diabetes mellitus	1.01e-06	1.01e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—AKT1—type 2 diabetes mellitus	9.95e-07	9.98e-06	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GSTM1—type 2 diabetes mellitus	9.83e-07	9.87e-06	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—LPL—type 2 diabetes mellitus	9.65e-07	9.68e-06	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ADCY5—type 2 diabetes mellitus	9.45e-07	9.48e-06	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GPX1—type 2 diabetes mellitus	9.42e-07	9.45e-06	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CD36—type 2 diabetes mellitus	9.17e-07	9.2e-06	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PPP2CA—type 2 diabetes mellitus	9.05e-07	9.09e-06	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—MTHFR—type 2 diabetes mellitus	8.69e-07	8.72e-06	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PPARA—type 2 diabetes mellitus	8.52e-07	8.55e-06	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—AGT—type 2 diabetes mellitus	8.26e-07	8.28e-06	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CALM1—type 2 diabetes mellitus	8.12e-07	8.15e-06	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—APOE—type 2 diabetes mellitus	8.09e-07	8.12e-06	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—APOA1—type 2 diabetes mellitus	8e-07	8.02e-06	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PPARG—type 2 diabetes mellitus	7.05e-07	7.07e-06	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—INS—type 2 diabetes mellitus	6.91e-07	6.93e-06	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ALB—type 2 diabetes mellitus	6.34e-07	6.36e-06	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—NOS3—type 2 diabetes mellitus	6.06e-07	6.08e-06	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PIK3R1—type 2 diabetes mellitus	6.06e-07	6.08e-06	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PTGS2—type 2 diabetes mellitus	5.54e-07	5.56e-06	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—AKT1—type 2 diabetes mellitus	2.79e-07	2.8e-06	CbGpPWpGaD
